A Phase 3 interventional study of insulin degludec and insulin detemir in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 81 sites in 12 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2019-06-13.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing insulin degludec in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. insulin degludec · Diabetes Mellitus, Type 1.
Among the 39 studies testing insulin degludec in Diabetes Mellitus, Type 1, this one is the 5th largest by enrollment, is one of 4 that started in 2012, is one of 7 in phase 3, and was the 18th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →None of the 39 studies testing insulin degludec in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 1 Year to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 350 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 38 across the 39 interventional studies. Of the 36 that completed or were terminated, 9 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 39 have an industry lead sponsor. The 9 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S: 2 open now, 5 under way, 1 of them phase 3. Of 220 finished, 33 (15%) have results posted.
Among the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, this one is the 29th largest by enrollment of the 149 interventional ones that give a count, is one of 14 that started in 2012, is one of 54 in phase 3, and was the 121st registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 1 studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing insulin degludec in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 226 in Diabetes Mellitus, Type 1:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Africa, Asia, Europe and the United States of America (USA).
The aim of this trial is to investigate the efficacy and safety of insulin degludec in children and adolescents with type 1 diabetes mellitus.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
This study's enrollment of 350 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Browse Diabetes Mellitus, Type 1 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin degludec · Drug: insulin aspart
Drug: insulin detemir · Drug: insulin aspart
Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
Injected subcutaneously (under the skin) once or twice daily. Dose individually adjusted.
Injected subcutaneously (under the skin) as mealtime bolus insulin. Dose individually adjusted.
Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%) at 26 Weeks (Analysed by Central Laboratory)
Change from baseline in HbA1c (%) after 26 weeks of treatment.
Time frame: Week 0, week 26
Change From Baseline in HbA1c (%) at 52 Weeks (Analysed by Central Laboratory)
Change from baseline in HbA1c (%) after 52 weeks of treatments.
Time frame: Week 0, week 52
Change From Baseline in Fasting Blood Glucose (FPG) at 26 Weeks (Analysed by Central Laboratory)
Change from baseline in FPG after 26 weeks of treatment.
Time frame: Week 0, week 26
Change From Baseline in Fasting Blood Glucose (FPG) at 52 Weeks (Analysed by Central Laboratory)
Change from baseline in FPG after 52 weeks of treatment.
Time frame: Week 0, week 52
Number of Treatment Emergent Adverse Events (TEAEs)
TEAE is defined as an event that has onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.
Time frame: After 26 weeks and 52 weeks of treatment
Number of Hypoglycaemic Episodes
Number of hypoglycaemic episodes (severe episodes or episodes with plasma glucose (PG) below or equal to 3.9 mmol/L (70 mg/dL) with or without symptoms of hypoglycaemia) during the trial; nocturnal \[11 p.m. - 7 a.m./23:00 - 07:00\] and over the entire day (24 hours)
Time frame: After 26 weeks and 52 weeks of treatment
Number of Self-measured Hyperglycaemia (Episodes of PG Above 11.1 mmol/L (200 mg/dL))
Episodes of PG \>11.1mmol/L (200mg/dL)
Time frame: After 26 weeks and 52 weeks of treatment
Number of Episodes With Self Monitored Blood Ketones Above 1.5 mmol (Capillary Blood Ketone Measurement to be Performed if Self-measured Plasma Glucose (SMPG) Exceeds 14.0 mmol/l (250 mg/dL))
Blood ketones \> 1.5mmol/L (Capillary blood ketone measurement to be performed if SMPG exceeds 14.0mmol/L (250mg/dL) )after 26 and 52 weeks of treatment
Time frame: After 26 weeks and 52 weeks of treatment
Steady-state Plasma Concentrations of Insulin Degludec and Insulin Detemir on Three Different Visits (Three Different Weeks) During the First 26 Weeks of Treatment
Steady state plasma concentrations of insulin degludec and insulin detemir on three different visits (three different weeks) during the trial.
Time frame: Between week 1 and week 26
Insulin Antibodies (Insulin Degludec Specific, Insulin Detemir Specific, Insulin Aspart Specific and Antibodies Cross-reacting to Human Insulin)
Antibody measurements : the values presented are week 52 (LOCF). The measurement of insulin antibodies after 26 and 52 weeks of treatment was done to fulfil the requirement of monitoring the long term immunogenicity. The unit of measure is percentage bound/total (%B/T) for these antibodies. The Antibodies cross reacting to Human Insulin is abbreviated as X-reacting AB Hu Insulin below)
Time frame: After 52 weeks of treatment
The trial was conducted at 72 sites in 12 countries as follows: Bulgaria (2), Finland (5), France (4), Germany (3), Italy (2), Japan (15), Netherlands (5), Republic of Macedonia (2), Russian Federation (6), South Africa (2), United Kingdom (4), United States (22)
| Milestone | IDeg + IAsp | IDet + IAsp |
|---|---|---|
| Started | 174 | 176 |
| Exposed | 174 | 175 |
| Completed | 170 | 165 |
| Not completed | 4 | 11 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Withdrawal by subject | 4 | 7 |
| Withdrew: Unclassified | 0 | 2 |
| Milestone | IDeg + IAsp | IDet + IAsp |
|---|---|---|
| Started | 152 | 128 |
| Completed | 151 | 122 |
| Not completed | 1 | 6 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 5 |
Change from baseline in HbA1c (%) after 26 weeks of treatment.
| percentage of glycosylated haemoglobin | IDeg + IAsp | IDet + IAsp |
|---|---|---|
| Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%) at 26 Weeks (Analysed by Central Laboratory) | -0.20 ± 0.95 | -0.31 ± 0.89 |
Change from baseline in HbA1c (%) after 52 weeks of treatments.
| percentage of glycosylated haemoglobin | IDeg + IAsp | IDet + IAsp |
|---|---|---|
| Change From Baseline in HbA1c (%) at 52 Weeks (Analysed by Central Laboratory) | -0.27 ± 1.07 | -0.22 ± 1.03 |
Change from baseline in FPG after 26 weeks of treatment.
| mmol/L | IDeg + IAsp | IDet + IAsp |
|---|---|---|
| Change From Baseline in Fasting Blood Glucose (FPG) at 26 Weeks (Analysed by Central Laboratory) | -0.67 ± 5.99 | 0.50 ± 8.37 |
Change from baseline in FPG after 52 weeks of treatment.
| mmol/L | IDeg + IAsp | IDet + IAsp |
|---|---|---|
| Change From Baseline in Fasting Blood Glucose (FPG) at 52 Weeks (Analysed by Central Laboratory) | -1.29 ± 6.53 | 1.10 ± 8.24 |
TEAE is defined as an event that has onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.
| events | IDeg + IAsp | IDet + IAsp |
|---|---|---|
| TEAEs -26 weeks | 810 | 761 |
| TEAEs -52 weeks | 1462 | 1266 |
Number of hypoglycaemic episodes (severe episodes or episodes with plasma glucose (PG) below or equal to 3.9 mmol/L (70 mg/dL) with or without symptoms of hypoglycaemia) during the trial; nocturnal \[11 p.m. - 7 a.m./23:00 - 07:00\] and over the entire day (24 hours)
| episodes | IDeg + IAsp | IDet + IAsp |
|---|---|---|
| 26 weeks (entire day) | 11712 | 10991 |
| 26 weeks (nocturnal) | 1261 | 1458 |
| 52 weeks (entire day) | 21560 | 18373 |
| 52 weeks (nocturnal) | 2336 | 2586 |
Episodes of PG \>11.1mmol/L (200mg/dL)
| episodes | IDeg + IAsp | IDet + IAsp |
|---|---|---|
| 26 weeks | 31264 | 31173 |
| 52 weeks | 58679 | 52831 |
Blood ketones \> 1.5mmol/L (Capillary blood ketone measurement to be performed if SMPG exceeds 14.0mmol/L (250mg/dL) )after 26 and 52 weeks of treatment
| episodes | IDeg + IAsp | IDet + IAsp |
|---|---|---|
| 26 weeks | 44 | 86 |
| 52 weeks | 109 | 161 |
Steady state plasma concentrations of insulin degludec and insulin detemir on three different visits (three different weeks) during the trial.
| pmol/L | IDeg + IAsp | IDet + IAsp |
|---|---|---|
| week 2 | 4540.4 ± 3999.0 | 3972.2 ± 6721.8 |
| week 12 | 4148.1 ± 3726.9 | 5430.1 ± 9067.7 |
| week 26 | 4105.6 ± 3456.5 | 6377.0 ± 10930.6 |
Antibody measurements : the values presented are week 52 (LOCF). The measurement of insulin antibodies after 26 and 52 weeks of treatment was done to fulfil the requirement of monitoring the long term immunogenicity. The unit of measure is percentage bound/total (%B/T) for these antibodies. The Antibodies cross reacting to Human Insulin is abbreviated as X-reacting AB Hu Insulin below)
| %B/T | IDeg + IAsp | IDet + IAsp |
|---|---|---|
| Insulin aspart specific antibodies | 1.1 ± 2.6 | 1.5 ± 2.3 |
| Insulin Detemir specific antibodies | NA ± NA | 6.1 ± 6.5 |
| Insulin Degludec specific antibodies | 0 ± 0.3 | NA ± NA |
| X-reacting AB Hu Insulin | 17.2 ± 7.7 | 26.0 ± 19.3 |
Collected over Treatment emergent events (after first trial product administration and no later than 7 days after last trial product administration). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IDeg + IAsp | — | 18/174 (10.3%) | 146/174 (83.9%) |
| IDet + IAsp | — | 16/175 (9.1%) | 143/175 (81.7%) |
| Event | IDeg + IAsp | IDet + IAsp |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 5/174 | 2/175 |
| Hypoglycaemic seizureNervous system disorders | 1/174 | 3/175 |
| AppendicitisInfections and infestations | 1/174 | 2/175 |
| GastroenteritisInfections and infestations | 1/174 | 2/175 |
| Gastroenteritis viralInfections and infestations | 0/174 | 2/175 |
| Blood ketone body increasedInvestigations | 1/174 | 2/175 |
| FaecalomaGastrointestinal disorders | 1/174 | 0/175 |
| BronchitisInfections and infestations | 1/174 | 0/175 |
| Respiratory tract infection viralInfections and infestations | 1/174 | 0/175 |
| Urinary tract infectionInfections and infestations | 1/174 | 0/175 |
| Event | IDeg + IAsp | IDet + IAsp |
|---|---|---|
| NasopharyngitisInfections and infestations | 72/174 | 67/175 |
| HeadacheNervous system disorders | 46/174 | 51/175 |
| Blood ketone body increasedInvestigations | 31/174 | 46/175 |
| Upper respiratory tract infectionInfections and infestations | 34/174 | 24/175 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 29/174 | 34/175 |
| CoughRespiratory, thoracic and mediastinal disorders | 31/174 | 28/175 |
| PyrexiaGeneral disorders | 30/174 | 28/175 |
| Abdominal pain upperGastrointestinal disorders | 28/174 | 17/175 |
| VomitingGastrointestinal disorders | 26/174 | 22/175 |
| HypoglycaemiaMetabolism and nutrition disorders | 26/174 | 17/175 |
Full Analysis set (FAS) included all randomised subjects.
| Age, Categorical(Participants) | IDeg + IAsp | IDet + IAsp | Total |
|---|---|---|---|
| <=18 years | 174 | 176 | 350 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | IDeg + IAsp | IDet + IAsp | Total |
|---|---|---|---|
| Female | 78 | 78 | 156 |
| Male | 96 | 98 | 194 |
Ran from Jan 2012 to primary completion in Jul 2013, 18 months.
Results were first posted in Jan 2016, 2 years 5 months after primary completion. A results delay was requested in Nov 2013.
Of 79 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's 18 months is close to that.
Counting every sponsor, half of 108 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin degludec · Insulin Detemir